Dual blockade of misfolded alpha-sarcoglycan degradation by bortezomib and givinostat combination
L. Hoch, N. Bourg, F. Degrugillier, C. Bruge, M. Benabides, E. Pellier, J. Tournois, G. Mahe, N. Maignan, J. Dawe, M. Georges, D. Papazian, N. Subramanian, S. Simon, P. Fanen, , X. Nissan
This study identifies givinostat as a potential therapeutic for LGMD R3 by inhibiting autophagy and enhancing bortezomib's effect on misfolded alpha-sarcoglycan degradation.
bioRxiv · Mar 16, 2022Pharmacology & Toxicology